Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle H Braccioforte

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Urology|November 26, 2008
Stereotactic transperineal prostate biopsyBrian J Moran, Michelle H Braccioforte
The Journal of Urology|September 6, 2006
Re-biopsy of the prostate using a stereotactic transperineal techniqueBrian J Moran, Michelle H Braccioforte, Dean J Conterato
Alzheimer Disease and Associated Disorders|June 18, 2010
Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer diseaseAnthony V D'Amico, Michelle H Braccioforte, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2009
Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancerAnthony V D'Amico, Michelle H Braccioforte, Brian J Moran, et al.
JAMA|August 27, 2009
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarctionAkash Nanda, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|October 16, 2020
Long-term outcomes of a prospective randomized trial of <sup>131</sup>Cs/<sup>125</sup>I permanent prostate brachytherapyBrian J Moran, Antony Koroulakis, Cristina Decesaris, et al.
European Urology Focus|July 30, 2017
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOTStephen A Mihalcik, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|February 26, 2011
Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practiceJona A Hattangadi, Ming-Hui Chen, Michelle H Braccioforte, et al.
International Journal of Radiation Oncology, Biology, Physics|January 22, 2013
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
Cancer|August 5, 2016
Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancerKonstantin A Kovtun, Ming-Hui Chen, Michelle H Braccioforte, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Urology|November 26, 2008
Stereotactic transperineal prostate biopsyBrian J Moran, Michelle H Braccioforte
The Journal of Urology|September 6, 2006
Re-biopsy of the prostate using a stereotactic transperineal techniqueBrian J Moran, Michelle H Braccioforte, Dean J Conterato
Alzheimer Disease and Associated Disorders|June 18, 2010
Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer diseaseAnthony V D'Amico, Michelle H Braccioforte, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|November 3, 2009
Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancerAnthony V D'Amico, Michelle H Braccioforte, Brian J Moran, et al.
JAMA|August 27, 2009
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarctionAkash Nanda, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|October 16, 2020
Long-term outcomes of a prospective randomized trial of <sup>131</sup>Cs/<sup>125</sup>I permanent prostate brachytherapyBrian J Moran, Antony Koroulakis, Cristina Decesaris, et al.
European Urology Focus|July 30, 2017
Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOTStephen A Mihalcik, Ming-Hui Chen, Michelle H Braccioforte, et al.
Brachytherapy|February 26, 2011
Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practiceJona A Hattangadi, Ming-Hui Chen, Michelle H Braccioforte, et al.
International Journal of Radiation Oncology, Biology, Physics|January 22, 2013
Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapyAkash Nanda, Ming-Hui Chen, Brian J Moran, et al.
Cancer|August 5, 2016
Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancerKonstantin A Kovtun, Ming-Hui Chen, Michelle H Braccioforte, et al.
Pageof 4